Debio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageRo 90-7501 is an inhibitor of amyloid ??42 (A??42) fibril assembly; reduces A??42-induced toxicity (EC50 = 2 ??M).
More Information Supplier PageRo 90-7501 is an inhibitor of amyloid ??42 (A??42) fibril assembly; reduces A??42-induced toxicity (EC50 = 2 ??M).
More Information Supplier PageRo 90-7501 is an inhibitor of amyloid ??42 (A??42) fibril assembly; reduces A??42-induced toxicity (EC50 = 2 ??M).
More Information Supplier PageRo 90-7501 is an inhibitor of amyloid ??42 (A??42) fibril assembly; reduces A??42-induced toxicity (EC50 = 2 ??M).
More Information Supplier PageMelanotan II is a high affinity melanocortin receptor agonist (Ki values are 0.67, 6.6, 34 and 46 nM for MC1, MC4, MC3 and MC5 receptors respectively).
More Information Supplier PageMelanotan II is a high affinity melanocortin receptor agonist (Ki values are 0.67, 6.6, 34 and 46 nM for MC1, MC4, MC3 and MC5 receptors respectively).
More Information Supplier PageMelanotan II is a high affinity melanocortin receptor agonist (Ki values are 0.67, 6.6, 34 and 46 nM for MC1, MC4, MC3 and MC5 receptors respectively).
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier PageDebio 0932 is a novel heat shock protein 90 (HSP90) inhibitor with strong affinity for HSP90 alpha/beta, high oral bioavailability and potent anti-proliferative activity against a broad range of cancer cell lines (with a mean IC50 of 220 nmol/L), including many non-small cell lung cancer (NSCLC) cell lines which are resistant to standard-of-care (SOC) agents.
More Information Supplier Page
